Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era

SIMPLE SUMMARY: The identification of activating mutations in specific genes in non-small cell lung cancer (NSCLC) has led to the development of targeted therapies, which are currently part of the algorithm for their management. The recommendations agree on first and second-line metastatic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Refeno, Valéry, Lamuraglia, Michele, Terrisse, Safae, Bonnet, Clément, Dumont, Clément, Doucet, Ludovic, Pouessel, Damien, Culine, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345514/
https://www.ncbi.nlm.nih.gov/pubmed/34359788
http://dx.doi.org/10.3390/cancers13153887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345514/
https://www.ncbi.nlm.nih.gov/pubmed/34359788
http://dx.doi.org/10.3390/cancers13153887

Ejemplares similares